Cellosaurus logo
expasy logo

Cellosaurus COLO201-AR (CVCL_4V91)

[Text][XML][JSON]
Cell line name COLO201-AR
Accession CVCL_4V91
Resource Identification Initiative To cite this cell line use: COLO201-AR (RRID:CVCL_4V91)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_90227; Selumetinib (AZD6244).
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
Sequence variations
  • Mutation; HGNC; HGNC:583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line).
Disease Colon adenocarcinoma (NCIt: C4349)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1987 (COLO 201)
Sex of cell Male
Age at sampling 70Y
Category Cancer cell line
Publications

PubMed=21098728; DOI=10.1126/scisignal.2001148; PMCID=PMC3372405
Ryan Bruce Corcoran, Dora Dias-Santagata, Kristin Bergethon, Anthony John Iafrate, Jeffrey Settleman, Jeffrey Adam Engelman;
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
Sci. Signal. 3:Ra84.1-Ra84.10(2010)

Cross-references
Cell line databases/resources cancercelllines; CVCL_4V91
Encyclopedic resources Wikidata; Q54814209
Entry history
Entry creation14-Dec-2015
Last entry update19-Dec-2024
Version number11